A new study has found that Chantix is eight time more likely to result in reports of suicidal behavior or depression compared to nicotine-replacement products.
The findings contradict those of the FDA that found Chantix did not increase the risk of being hospitalized for psychiatric problems such as depression.
The authors of this new study stated that the FDA hospitalization studies were flawed because they could not capture most of the serious psychiatric side effects, including suicide, depression, aggression, and assaults.
Another reason FDA failed to ascertain the magnitude of the problem with Chantix is they omitted suicidal and depression events that did not lead to hospitalization. These can be catastrophic events but do not normally result in hospitalization.